Table 1.
|
|
Wild type |
Ob/ob |
DKO |
||||||
---|---|---|---|---|---|---|---|---|---|---|
Condition | Sham | NP | P | Sham | NP | P | Sham | NP | P | |
PRSW (mmHg) |
Untreated |
87.9±5.0 |
60.2±11.8c |
76.3±5.4 cd |
64.5±2.5 a |
48.1±3.6 ac |
57.1±5.2 acd |
58.0±4.1 af |
48.6±6.5 ac |
49.2±3.0 acf |
Diet |
|
|
|
65.8±1.7 |
50.4±1.0 c |
64.4±3.1 bd |
58.2±3.0 f |
49.5±3.2 c |
55.9±3.5 bdf |
|
ACE-I |
88.0±4.6 |
59.3±6.8 c |
81.2±3.1 bcd |
72.4±3.1 abe |
52.3±3.6 ac |
69.8±2.9 abde |
65.9±5.3 abef |
51.1±3.6 ac |
63.9±3.3 abdef |
|
Ees (mmHg/μl) |
Untreated |
8.3±2.5 |
6.4±1.5 |
8.5±1.7 d |
5.0±0.4 a |
4.8±1.7 |
5.6±1.2 a |
6.0±2.2 |
4.5±0.8 a |
4.8±2.3 a |
Diet |
|
|
|
6.3±2.2 |
4.4±1.2 |
7.3±2.2d |
5.1±1.3 |
5.4±1.2 |
5.6±1.1 |
|
ACE-I |
6.0±1.1 |
6.2±1.6 |
8.7±1.7 cd |
5.3±1.7 |
4.2±1.3 |
6.4±1.6 ad |
5.6±1.4 |
4.3±1.4 |
5.2±3.0 a |
|
EDPVR (mmHg/μl) | Untreated |
0.2±0.2 |
0.4±0.2 |
0.3±0.2 |
0.4±0.3 |
0.4±0.3 |
0.5±0.3 a |
0.5±0.4 |
0.3±0.1 |
0.3±0.2 |
Diet |
|
|
|
0.3±0.2 |
0.2±0.1 |
0.2±0.1 b |
0.3±0.1 |
0.2±0.1 b |
0.3±0.2 |
|
ACE-I | 0.2±0.2 | 0.4±0.4 | 0.2±0.1 | 0.4±0.1 | 0.3±0.1 | 0.3±0.1 bc | 0.3±0.1 f | 0.3±0.1 | 0.2±0.1 |
ACE-I: angiotensin-converting enzyme inhibition; DKO: double knock-out (ob/ob; LDLR-/-); EDPVR: end-diastolic pressure-volume relationship; Ees: end-systolic elastance; IR: ischemia/reperfusion; NP: Non-Preconditioned and ischemia/reperfusion; P: Preconditioned and ischemia/reperfusion; PRSW: preload recruitable stroke work; sham: group without ischemia/reperfusion. “a” p<0.05 versus WT same treatment, same condition (sham; non-preconditioned; preconditioned); “b” p<0.05 versus same untreated genotype, same condition; “c” p<0.05 versus sham, same genotype, same treatment; “d” p<0.05 versus non-preconditioned, same genotype, same treatment; “e” p<0.05 versus diet, same genotype, same condition; “f” p<0.05 versus ob/ob same treatment, same condition.